Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061371
Free PMC article.
Clinical Trial.
Prespecified subgroups of eGFR included 2282 (34.5%) participants with an eGFR of less than 30 mL/min per 1.73 m(2), 2928 (44.3%) with an eGFR of 30 to less than 45 mL/min per 1.73 m(2), and 1399 (21.2%) with an eGFR 45 mL/min per 1.73 m(2) or higher. ...Over …
Prespecified subgroups of eGFR included 2282 (34.5%) participants with an eGFR of less than 30 mL/min per 1.73 m(2), 2928 (44.3%) wit …
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators.
Miles D, et al.
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
Ann Oncol. 2021.
PMID: 34219000
Free article.
Clinical Trial.
PATIENTS AND METHODS: Eligible patients [no prior systemic therapy or 12 months since (neo)adjuvant chemotherapy] were randomised 2:1 to atezolizumab 840 mg or placebo (days 1, 15), both with paclitaxel 90 mg/m(2) (days 1, 8, 15), every 28 days until disease progression or …
PATIENTS AND METHODS: Eligible patients [no prior systemic therapy or 12 months since (neo)adjuvant chemotherapy] were randomised 2:1 to ate …
Item in Clipboard
Cite
Cite